Scientists at the University of California, Irvine, introduced glycan-dependent T cell recruiter (GlyTR) compounds that selectively bind tumor-associated carbohydrate antigens to trigger potent pan-cancer immune responses. This bispecific antibody approach overcomes the challenge of on-target toxicity seen in protein antigen targeting by exploiting velcro-like density-dependent binding. Preclinical models across multiple solid tumor types demonstrated strong efficacy and safety, offering a promising universal immunotherapy strategy.